Table 3 Patient-specific cancer organoids biobank characteristics
From: Translational models of 3-D organoids and cancer stem cells in gastric cancer research
| Â | Vlachogiannis et al. [48] | Seidlitz et al. [47] | Yan et al. [50] | Nanki et al. [49] | Ukai et al. [51] |
|---|---|---|---|---|---|
Tissue origin | Ultrasound CT-guided biopsy | Surgical resection | Surgical resection | Surgical resection Endoscopic biopsy Ascites punctures | Surgical resection Endoscopic biopsy |
Organoid library | |||||
Cancer | 4 | 20 | 46 | 37 | 20 |
Normal | − | 3 | 17 | 6 | 10 |
Patients with clinical trails | + | − | - | - | - |
Tissue digestion | TrypLE (2 x) EDTA (1 mM) | Dispase II (1 mg/ml) Collagenase (0.6 mg/ml) | Collagenase XI ( 0.1 μg/μl) Hyaluronidase (20 μg/μl) | Libease H TrypLE Express | Partec CellTrics (Sysmex, Hyogo, Japan) EDTA (1 mM) |
Medium composition | |||||
WNT3A | 100Â ng/ml | 50% | 50% | 25% | 25% |
R-spondin | 500 ng/ml | 10% | 10% | 1 μg/μl | 1 μg/μl |
Noggin | 100Â ng/ml | 10% | 10% | 100Â ng/ml | 100Â ng/ml |
B27 | 1x | 1x | 1x | 1x | 1x |
N2 | 1x | 1x | − | − | − |
Nicotinamide | 4 mM | 10 mM | − | − | − |
NAc-Cys | − | 1 mM | 1 mM | 1 mM | 1 mM |
hFGF10 | 10Â ng/ml | 200Â ng/ml | 200Â ng/ml | 50Â ng/ml | 50Â ng/ml |
hFGF10-basic | 10 ng/ml | − | − | − | − |
mEGF | 50Â ng/ml | 50Â ng/ml | 50Â ng/ml | 50Â ng/ml | 50Â ng/ml |
Gastrin | 10Â nM | 1Â nM | 1Â nM | 10Â nM | 10Â nM |
A83-01 | 0.5 μM | 2 μM | 2 μM | 500 nM | 500 nM |
Y-27632 | 10 μM | 10 μM (only for initial stage) | 10 μM | − | 10 μM (only for initial stage) |
Prostaglandin E2 | 1 μM | − | − | − | − |
SB202190 | 5 μM | − | − | − | − |
Selection of cancer organoids from prevent normal organoid-overgrowth | − | − | + | + | + |
Selection via |  |  | 1. Microscopically organoid picking 2. Nutlin3a (10 μM) | 1. Plus Nutlin3a (3 μM) minus Y-27632 2. Minus A83-01 plus TGFβ (10 ng/ml) 3. Minus EGF and FGF18 | 1. Microscopically organoid picking 2. Drug resistant GCOs clones with selected by 5-FU, puromycin, and G418 |